Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to HER2-negative Breast Cancer
Related studies linked through entity extraction aliases.
Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE4
Role of the Immune Environment in Response to Therapy in Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
Onvansertib + Paclitaxel In TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
- Status
- RECRUITING
- Phase
- PHASE4
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
(VELA) Study of BLU-222 in Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2